Article Details

Sigilon Therapeutics Appoints David E. Moller, MD, as Chief Scientific Officer

Retrieved on: 2018-01-03 23:00:00

Tags for this article:

Click the tags to see associated articles and topics

Sigilon Therapeutics Appoints David E. Moller, MD, as Chief Scientific Officer. View article details on hiswai:

Excerpt

<div>Dr. Moller brings a long history of experience in drug discovery and development to the company, including a focus on development of therapeutics for metabolic disorders and in the identification and evaluation of <b>emerging technologies</b>. "Dr. Moller's experience provides an ideal fit for the Sigilon ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up